100 episodes
ACCEL Lite: Featured ACCEL Interviews on Exciting CV Research American College of Cardiology
-
- Health & Fitness
-
-
3.7 • 39 Ratings
-
The American College of Cardiology offers select interviews and summaries of cardiology’s most interesting research areas from ACCEL’s renowned library, hosted by ACCEL Editor-in-Chief Alison L. Bailey, MD, FACC, FAACPVR.
-
ESC Hot Line: STEP HFpEF: Once-Weekly Semaglutide in People with HFpEF and Obesity
Currently no approved therapies exist to target obesity-related heart failure with preserved ejection fraction, a condition increasing in prevalence and associated with high symptom burden. In this interview, Mikhail Kosiborod MD, and Alison L. Bailey MD, FACC, discuss ESC Hot Line: STEP HFpEF: once-weekly semaglutide in people with HFpEF and obesity.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL -
ACCEL Lite: ESC Hot Line: CLEAR Outcomes Total Events Analysis
Results presented at the European Society of Cardiology Congress 2023 further support the long-term use of bempedoic acid in patients at high-risk of cardiovascular events and demonstrate particular benefit in those with diabetes. In this interview, Stephen J. Nicholls MBBS, PhD, FACC and Erin D. Michos, MD, MHS, FACC, discuss the total events analysis from the CLEAR Outcomes trial.
This ACCEL episode is part of an ACC course titled Bempedoic Acid: New Evidence Transforming the LDL-C Treatment Landscape. Educational grant support is provided by Esperion. More content will be available here soon.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL -
ACEL Lite: ESC Late-Breaker: RATE-AF Trial Wearables Study
What is known about the use of wearables and their impact on health outcomes and healthcare use among patients with atrial fibrillation.
In this interview, Dipak Kotecha MBChB, PhD and Sidney C. Smith Jr. MD, MACC, discuss “ESC Late-Breaker: RATE-AF trial wearables study.”
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL -
ACCEL Lite: ESC Late-Breaker: INTERASPIRE: An International Survey of Secondary prevention of CVD
In selected countries from each of the six WHO regions, the INTERASPIRE survey is being conducted to provide a unique picture of CHD patients, their cardiometabolic, renal and biomarker status, lifestyle and therapeutic management, and the quality of preventive care in their region.
In this interview, John W. McEvoy MB, BCh, BAO, MHS, and William E. Boden MD, FACC discuss INTERASPIRE: An International Survey of Secondary Prevention of CVD.
Subscribe on Apple Podcasts Subscribe on Google Play Subscribe to ACCEL -
ACCEL Lite: Contemporary Therapy in PAD That Every Cardiologist Should Know
Understanding, recognizing and effectively treating PAD has the potential to dramatically alter a patient’s life. A patient’s ability to walk, quality of life, and longevity can all be profoundly impacted.
In this interview, Sasanka Jayasuriya, MD, FACC, Douglas Weaver MD, MACC, and Sun Moon Kim MD, FSCAI, FACC, discuss Contemporary Therapy in PAD That Every Cardiologist Should Know.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL -
ACCEL Lite: Renal Considerations in the Management of Heart Failure
Cardiorenal syndromes cause fluid retention and venous congestion that, in turn, damages the function of vital organs. Providers should have zero tolerance for excessive fluid retention. Aggressive diuretic treatment seems particularly beneficial in patients who are hospitalized for decompensated heart failure.
In this interview, Paolo Colombo MD, FACC, and William E. Boden MD, FACC, FAHA, discuss Renal Considerations in the Management of Heart Failure.
Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL
Customer Reviews
ACCEL
I always enjoyed the prior ACCEL recordings that were very informative. The ACCEL lite interviews are interesting but lack the depth of the previous longer interview format.
This is a joke
I listened to the real ACCEL for decades. This new version, properly referred to as “lite” is superficial, skin deep really. Too much time with smarmy introductory exchanges and meaningless polite banter and god forbid if the moderator dares to not recite all the letters after a speakers name. ACCEL Lite is a joke. I pray for the ACC to bring back the real ACCEL.
Dumbing down of a formerly excellent program
For decades, ACCEL has served as a wonderful educational program. This is no longer the case. Reversion to the original format would constitute a wonderful service to both active members of the ACC and trainees.